Skip to the content
logo mainlogo darklogo light
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers
logo mainlogo darklogo light
HomePosted by Edison Oncology
Press Release

Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent Pediatric Cancers

Edison Oncology
April 8, 2024
Press Release News

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting

Edison Oncology
April 20, 2023
Presentations and Publications

A Phase 1-2 clinical trial of EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration

Edison Oncology
August 1, 2022
Presentations and Publications

An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001 – a novel irreversible pan-ErbB inhibitor with promising brain penetration – in patients with advanced cancer

Edison Oncology
June 1, 2022
Presentations and Publications

A Pilot Pharmacokinetic Clinical Study of VAL-413 (Orotecan®) in Patients with Recurrent Pediatric Solid Tumors

Edison Oncology
June 1, 2022
Press Release

Edison Oncology Announces Treatment of First Patient in Orotecan® (irinotecan HCI oral solution) Phase I/IIa Clinical Trial for Patients with Recurrent Pediatric Solid Tumors

Edison Oncology
February 17, 2022
Press Release

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Edison Oncology
September 30, 2021
Press Release

Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics

Edison Oncology
April 1, 2021
Press Release

Edison Oncology to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Edison Oncology
February 16, 2021
Press Release

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Edison Oncology
February 9, 2021

Posts pagination

1 2
Recent Updates

Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent Pediatric Cancers

Edison Oncology
April 8, 2024

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting

Edison Oncology
April 20, 2023
Categories
News Presentations and Publications Press Release
w
Contact us today
View more

Company

  • Leadership Team
  • About
  • Careers

Information

  • Technology
  • Product Pipeline
  • Press Releases

Menlo Park, CA

  • 3475 Edison Way,
    Suite R
    Menlo Park, CA 94025

© 2025 Edison Oncology, All Rights Reserved

Back to top Drag
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers

John K. Bell

Independent Board Member

John K. Bell serves as lead independent director and chair of the audit committee.

Mr. Bell is the founder of Shred-Tech Ltd. and Polymer Technologies, Inc., John K. Bell is a businessperson who has been the head of 15 different companies and presently is Chairman at CrossChasm Technologies, Inc., Chairman & Chief Executive Officer at Onbelay Investment Corp., Chairman for Stack Capital Group, Inc., lead independent director of Edison Oncology Holding Corp., and Director & Governor at Stratford Festival. He is also on the board of Stratford Shakespearean Festival of America.

Mr. Bell was a founding investor of Research in Motion (Blackberry) and previously held the position of Director at Canopy Growth Corp. and Chairman of Canopy Rivers Corp. (a subsidiary of Canopy Growth Corp.), Chairman of Waterloo Regional Police Service, Chairman of Prosperity Council of Waterloo Region, Director at RIV Capital, Inc., Chief Executive Officer & Director at ATS Corp., Chief Executive Officer & Owner at Shred-Tech Ltd., Director at BSM Technologies, Inc., Director at BSM Technologies Ltd., Chairman of HEXO Corp., President & Chief Executive Officer of Polymer Technologies, Inc., Chairman of Cambridge Memorial Hospital, Member of Institute of Corporate Directors and Secretary & Director at Crohn’s & Colitis Foundation of Canada.

John K. Bell received an undergraduate degree from Richard Ivey School of Business.